Abselion has expanded its Amperia benchtop platform with a new Protein G Total Antibody Quantification Kit, designed to simplify measurement of a broader range of antibody isotypes and species. The launch reflects the company’s commitment to practical, application-driven tools for antibody discovery and development, aiming to reduce analytical bottlenecks and accelerate research decisions.

The new kit complements Abselion’s existing Protein A-based format, allowing researchers to maintain the same workflow while covering antibodies that Protein A binds less efficiently. Dr Ruizhi Wang, CEO and founder of Abselion, said: “Antibody-based research and development often involves a wide variety of formats, subclasses, and species. Having the flexibility to choose the most appropriate assay without adjusting workflows can simplify decision-making and improve efficiency.”

Amperia uses an electrochemical readout that removes the need for optics or fluidics, offering fast, accurate quantification in a compact benchtop instrument. Protein G-coated sensor strips capture antibodies from purified or partially purified samples, while a labelled detection molecule binds to remaining Fc-binding sites. The inverse occupancy assay produces a signal inversely proportional to antibody concentration, enabling rapid, reproducible results.

For researchers familiar with the Protein A kit, Dr Wang stressed that the workflow remains identical. “The key difference is binding specificity: Protein G extends coverage to antibody isotypes and species that are less well captured by Protein A, while maintaining the same levels of accuracy, reproducibility, and ease of use,” he said. “There is no need for additional training or changes in sample preparation.”

Independent benchmarking supports Amperia’s performance. In a study by Agenus UK, Amperia measurements closely aligned with results from bio-layer interferometry (BLI) and surface plasmon resonance (SPR), confirming comparable accuracy with simpler setup and faster turnaround. While external validation of the Protein G kit is ongoing with biopharma partners, internal testing has shown consistent accuracy across multiple isotypes, making it suitable for both research and early process development applications.

The platform also handles crude samples such as cell culture supernatants, allowing meaningful titre data to be generated earlier in development. Dr Wang added: “In practice, results are most reliable when samples and calibration standards are prepared in comparable buffers, but the system works equally well with purified material.” Typical throughput is up to 64 samples per 2–3 hour run, with minimal hands-on time, enabling several runs per day without intensive operator input.

Amperia is already in use at multiple academic and healthcare institutions, including NHS Blood and Transplant and the universities of Kent and Manchester, as well as several biopharma and CDMO partners. Feedback highlights the ease of use, rapid turnaround, and flexibility to analyse a wide variety of samples as major advantages.

Dr Wang explained the broader impact: “Expanding our antibody quantification offering with Protein G allows us to better support scientists working across discovery and development. By enabling accurate, reproducible measurements without complex setup, we help teams make faster, better-informed decisions that streamline workflows and reduce delays in development pipelines.”

While currently positioned for research use, Amperia undergoes rigorous factory testing and quality control, ensuring reliability for current applications and creating a strong foundation for potential adaptation to regulated environments in the future. The Protein G kit is priced in line with the Protein A format, providing labs with flexibility without added cost, and its electrochemical detection approach significantly reduces capital and maintenance requirements compared with BLI or SPR.